MedTrace Logo

Brain Small Chain Fatty Acid Metabolism in Parkinson Disease: Tributyrin Supplementation

NCT05446168 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 18

Last updated 2025-01-23

Study results available
· View outcomes & findings →

Summary

Small exploratory open-label pilot study to assess the short-chain fatty acid (SCFA) prodrug tributyrin as a potential therapy for persons with Parkinson disease

Conditions

  • Parkinson Disease

Interventions

DRUG

tributyrin

Post-biotic short chain fatty acid dietary supplement. Participants will take 500mg TID tributyrin supplement for 30 days +/- 7 days.

Sponsors & Collaborators

  • Nicolaas Bohnen, MD, PhD

    lead OTHER

Principal Investigators

  • Nicolaas I Bohnen, MD, PhD · University of Michigan

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
45 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-07-01
Primary Completion
2023-09-26
Completion
2023-09-26
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05446168 on ClinicalTrials.gov